Back

The NOAH- AFNET 6 study: design and update.

19 March 2018 (13:14 - 13:26)
Organised by:
Congress Presentation Part of: Challenges and current insights for the management of atrial high rate episodes Atrial Fibrillation - Stroke Prevention - Oral Anticoagulation EHRA Premium Access EHRA 2018

About the speaker

Photo
Professor Andreas Goette

Saint Vincenz Hospital Paderborn, Paderborn (Germany)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction - Challenges and current insights for the management of atrial high rate episodes.
Professor A. Goette (Paderborn, DE) Professor P. Kirchhof (Hamburg, DE)
Presentation thumbnail
Uncertainties in the management of patients with atrial high rate episodes.
Professor S. Freedman (Sydney, AU)
Presentation thumbnail
Management of patients with atrial high rate episodes: how do we do it in Dresden?
Doctor C. Axthelm (Dresden, DE)
Presentation thumbnail
Panel discussion.
Professor P. Kirchhof (Hamburg, DE) Professor A. Goette (Paderborn, DE)
Presentation thumbnail
Conclusion - Summary: challenges and current insights for the management of atrial high rate episodes.
Professor P. Kirchhof (Hamburg, DE) Professor A. Goette (Paderborn, DE)

Access the full session

Session thumbnail
Challenges and current insights for the management of atrial high rate episodes

The Event

Event poster

EHRA 2018

19 March 2018 13:14 CET
You may be interested in
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
9 April 2024
thumbnail
Webinar
Are NOACs already outdated? New trends in anticoagulation therapy
12 December 2022
thumbnail
Congress Presentation
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources